Palvella Therapeutics, Inc. (PVLA) Operating Margin
- Operating margin · 12 months: Value (m); Formula and calculation Operating income / revenue. Period ending 2026-06-30..
Operating margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Operating margin · 12 months | (m) | Operating income / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating income | -57.74M USD | Operating Income (Loss) |
| Revenue | (m) | Revenue from Contract with Customer, Excluding Assessed Tax |
| Cost of products and services | (m) | |
| Research and development | 35.46M USD | Research and Development Expense |
| Selling, general and administration | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Operating income (USD) | Revenue (USD) | Cost of products and services (USD) | Research and development (USD) | Selling, general and administration (USD) | Operating margin |
|---|---|---|---|---|---|---|
| 2026-06-30 | $-57.74M | (m) | (m) | $35.46M | (m) | (m) |
| 2026-03-31 | $-45.59M | (m) | (m) | $28.10M | (m) | (m) |
| 2025-12-31 | $-38.60M | (m) | (m) | $22.84M | (m) | (m) |
| 2025-09-30 | $-31.66M | (m) | (m) | $18.26M | (m) | (m) |
| 2025-06-30 | $-26.55M | (m) | (m) | $14.92M | (m) | (m) |
| 2025-03-31 | $-20.21M | (m) | (m) | $11.24M | (m) | (m) |
| 2024-12-31 | $-14.10M | (m) | (m) | $8.15M | (m) | (m) |
| 2024-09-30 | $-17.12M | $1.35M | (m) | (m) | (m) | -1265.98% |
| 2024-06-30 | $-25.79M | $20.87M | (m) | $16.02M | (m) | -123.55% |
| 2024-03-31 | $-19.55M | $40.93M | (m) | $29.59M | (m) | -47.76% |
| 2023-12-31 | $-29.76M | $42.81M | (m) | $41.80M | (m) | -69.51% |
| 2023-09-30 | $-36.77M | $47.36M | (m) | $50.73M | (m) | -77.65% |
| 2023-06-30 | $-37.13M | $33.21M | (m) | $54.72M | (m) | -111.83% |
| 2023-03-31 | $-51.53M | $16.85M | (m) | $52.34M | (m) | -305.80% |
| 2022-12-31 | $-43.47M | $25.90M | (m) | $52.98M | (m) | -167.84% |
| 2022-09-30 | $-42.95M | $28.50M | (m) | $54.96M | (m) | -150.72% |
| 2022-06-30 | $-49.80M | $27.19M | (m) | $60.31M | (m) | -183.18% |
| 2022-03-31 | $-54.23M | $26.77M | (m) | $64.16M | (m) | -202.55% |
| 2021-12-31 | $-51.83M | $31.42M | (m) | $66.66M | (m) | -164.97% |
| 2021-09-30 | $-53.24M | $24.85M | (m) | $61.92M | (m) | -214.24% |
| 2021-06-30 | $-47.23M | $23.73M | (m) | $54.80M | (m) | -199.00% |
| 2021-03-31 | $-35.12M | $31.70M | (m) | $50.34M | (m) | -110.82% |
| 2020-12-31 | $-33.92M | $29.32M | (m) | $46.53M | (m) | -115.68% |
| 2020-09-30 | $-22.84M | $44.13M | (m) | $50.03M | (m) | -51.76% |
| 2020-06-30 | $-12.76M | $55.69M | (m) | $51.42M | (m) | -22.91% |
| 2020-03-31 | $-20.33M | $49.37M | (m) | $53.46M | (m) | -41.18% |
| 2019-12-31 | $-27.16M | $43.65M | (m) | $55.00M | (m) | -62.22% |
| 2019-09-30 | $-38.48M | $33.53M | (m) | $53.88M | (m) | -114.76% |
| 2019-06-30 | $-43.37M | $26.90M | (m) | $52.07M | (m) | -161.20% |
| 2019-03-31 | $-33.38M | $33.19M | (m) | $47.85M | (m) | -100.56% |
| 2018-12-31 | $-30.83M | $29.10M | (m) | $41.49M | (m) | -105.94% |
| 2018-09-30 | $-11.70M | $42.34M | (m) | $33.76M | (m) | -27.62% |
| 2018-06-30 | $-9.08M | $37.92M | (m) | $28.62M | (m) | -23.93% |
| 2018-03-31 | $-14.72M | $28.08M | (m) | $24.86M | (m) | -52.43% |
| 2017-12-31 | $-14.59M | $25.27M | (m) | $22.29M | (m) | -57.74% |
| 2017-09-30 | $-27.49M | $9.85M | (m) | $23.93M | (m) | -279.06% |
| 2017-06-30 | $-28.48M | $6.71M | (m) | $22.29M | (m) | -424.61% |
| 2017-03-31 | $-26.38M | $5.93M | (m) | $21.40M | (m) | -445.12% |
| 2016-12-31 | $-22.76M | $5.83M | (m) | $19.70M | (m) | -390.33% |
| 2016-09-30 | $-18.92M | $5.24M | (m) | $15.72M | (m) | -360.79% |
| 2016-06-30 | $-16.62M | $4.87M | (m) | $13.15M | (m) | -341.05% |
| 2016-03-31 | $-14.36M | $3.96M | (m) | $10.38M | (m) | -362.55% |
| 2015-12-31 | $-13.68M | $2.93M | (m) | $8.24M | (m) | -466.62% |
| 2015-09-30 | $-13.03M | $4.07M | (m) | $7.63M | (m) | -320.37% |
| 2015-06-30 | $-10.99M | $3.67M | (m) | $6.51M | (m) | -299.39% |
| 2015-03-31 | $-10.23M | $4.21M | (m) | $5.90M | (m) | -242.97% |
| 2014-12-31 | $-7.20M | $5.37M | (m) | $5.60M | (m) | -134.17% |
| 2014-09-30 | $-23.87K | $0.00 | (m) | (m) | (m) | (m) |
| 2014-06-30 | $-15.71K | $0.00 | (m) | (m) | (m) | (m) |
| 2014-03-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2013-12-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2013-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2013-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |